The reality is that Actinogen continues to disappoint on now a regular basis its long suffering shareholders. That’s what the market is saying. No amount of sugar coating will change the prevailing sentiment.
All this depression stuff was not the primary end point for Actinogen. The company’s main drug was designed to prove some level of effectiveness for cognition & alzheimers. Despite some positive studies in the past, this time it has again failed to meet this fundamental proof of concept between cortisol and cognition. That’s why the market is where it is.
The reality is that Actinogen continues to disappoint on now a...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
0.001(4.76%) |
Mkt cap ! $69.89M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.2¢ | 2.1¢ | $25.07K | 1.166M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1912322 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 1275051 | 7 |
View Market Depth
| Last trade - 12.05pm 25/06/2025 (20 minute delay) ? |
| ACW (ASX) Chart |